SCHEMBL2230276

SCHEMBL2230276

CCCCCCCC(=O)CCC(=O)ON

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.55
MAPT P10636 1/20 0.55
HTR2C P28335 1/20 0.51
DGKA P23743 1/20 0.48
CES2 O00748 3/20 0.46
CES1 P23141 3/20 0.46
LMNA P02545 2/20 0.46
HAO1 Q9UJM8 1/20 0.46
GPR84 Q9NQS5 6/20 0.45
PPARG P37231 6/20 0.45
PPARD Q03181 6/20 0.45
PPARA Q07869 6/20 0.45
HDAC11 Q96DB2 5/20 0.45
TSHR P16473 4/20 0.45
ALDH1A1 P00352 2/20 0.45
TLR2 O60603 2/20 0.45
TDP1 Q9NUW8 2/20 0.45
FABP4 P15090 2/20 0.45
PTPN1 P18031 2/20 0.45
SLC22A6 Q4U2R8 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28932569 1.00 KMT2A (0.55) KMT2AMAPTHTR2CDGKACES2
SCHEMBL28017366 0.98 KMT2A (0.53) KMT2AMAPTHTR2CDGKACES2
SCHEMBL27403983 0.94 MAPT (0.57) KMT2AMAPTDGKACES2CES1
SCHEMBL28921483 0.94 MAPT (0.57) KMT2AMAPTDGKACES2CES1
SCHEMBL29172607 0.90 MAPT (0.53) KMT2AMAPTDGKACES2CES1
SCHEMBL394559 0.87 DGKA (0.61) KMT2AMAPTDGKACES2CES1
SCHEMBL905880 0.87 DGKA (0.61) KMT2AMAPTDGKACES2CES1
SCHEMBL225274 0.87 DGKA (0.61) KMT2AMAPTDGKACES2CES1
SCHEMBL337904 0.87 DGKA (0.61) KMT2AMAPTDGKACES2CES1
SCHEMBL8683587 0.87 DGKA (0.61) KMT2AMAPTDGKACES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170267766-A1 IGF-1R ANTIBODY AND ITS USE AS ADDRESSING VEHICLE FOR THE TREATMENT OF CANCER PIERRE FABRE MEDICAMENT (FR) 2017-09-21 US disclosed
US-9624308-B2 Antigen binding proteins PIERRE FABRE MEDICAMENT (FR) 2017-04-18 US disclosed
EP-3134438-A1 IGF-1R ANTIBODY AND ITS USE AS ADDRESSING VEHICLE FOR THE TREATMENT OF CANCER Pierre Fabre Médicament (FR) 2017-03-01 EP disclosed
US-20160046725-A1 NOVEL ANTIGEN BINDING PROTEINS AND THEIR USE AS ADDRESSING PRODUCT FOR THE TREATMENT OF CANCER PIERRE FABRE MEDICAMENT (FR) 2016-02-18 US disclosed
WO-2015162292-A1 IGF-1R ANTIBODY AND ITS USE AS ADDRESSING VEHICLE FOR THE TREATMENT OF CANCER PIERRE FABRE MEDICAMENT (FR) 2015-10-29 WO disclosed
EP-2914630-A1 NOVEL ANTIGEN BINDING PROTEINS AND THEIR USE AS ADDRESSING PRODUCT FOR THE TREATMENT OF CANCER Pierre Fabre Médicament (FR) 2015-09-09 EP disclosed
WO-2014068139-A1 NOVEL ANTIGEN BINDING PROTEINS AND THEIR USE AS ADDRESSING PRODUCT FOR THE TREATMENT OF CANCER PIERRE FABRE MEDICAMENT (FR) 2014-05-08 WO disclosed
WO-2011089216-A1 DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS ASCENDIS PHARMA AS (DK) 2011-07-28 WO disclosed